Envita's Aait A Powerful Immunotherapy For Cancer

By Author: Henry Wronger
Total Articles: 6
Comment this article

AAIT is an acronym for autologous adoptive immune therapy and defines a therapy derived from a patient’s own blood, which is re-infused during cancer treatment. There are abundant strategies for Immunotherapy and just as many treatments that can be referenced as “autologous adoptive immunotherapy.” Clearly, not all options are deemed comparable.

Envita’s immunotherapy, AAIT, involves 4 major cell types which include Natural killer cells Natural killer T cells, Cytokine-induced killer cells, Cytotoxic T lymphocytes – where the inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the predominant focus of Envita’s AAIT immunotherapy serums.

Natural Killer Cells Important in Cancer Prognosis of Cancer
When NK cell numbers and functionality are low, cancer patients are predisposed to more aggressive tumor growth. And, as disease progresses, such declines are likely to continue. In both animal and human clinical trials, we have seen that by restoring NK and NKT function leads to enhanced cellular ...
... immune tumor-response and higher patient survival rates.
Keys to Envita's AAIT Immunotherapy Uniqueness

1) Envita's protocol for AAIT immunotherapy is designed to optimize the expansion of natural killer cells - the most potent cancer fighting component of the cellular immune system. Most immunotherapy treatments do not include natural killer cells, and those that do only expand them in low numbers with little activation.

2) Envita's AAIT immunotherapy protocol takes only 4-5 weeks to grow your cells, so you can begin to experience benefits quickly. Moreover, while other immune therapies administer just 100-200 million cells per treatment, Envita delivers roughly 100 times as many during the course of your treatment.

3) Multitudes of published studies demonstrate the effects of adoptive immunotherapy for cancer patients among which Envita has identified and improved upon the best. Company protocol insists upon the highest-level of procedure for Lyme disease the expansion and application of cells for each immunotherapy treatment.

4) Unlike other published immune therapies, Envita's AAIT is the only one that can be used as a “stand-alone.” Moreover, it may also be administered in conjunction with other therapies to enhance the cells’ effects in patients – an incomparable benefit. Envita's AAIT immunotherapy is not focused solely on expanding cells in the lab; rather, our goal also includes keeping them active until reintroduced to the patient’s body.

5) Envita’s AAIT immunotherapy vaccine offers far greater tumor kill, or cytotoxicity than that of other well-regarded cancer cell vaccines / immunotherapy treatments found throughout the world. In brief, this means Envita’s activated natural killer cells in AAIT immunotherapy deliver considerably higher tumor obliteration.

6) In summary, the most direct manner to stack Envita’s proprietary immunotherapy against the others includes its:

a. Quality - based on cytoxicity (how much tumor the immune system can kill). Envita’s AAIT immunotherapy consistently delivers “significantly greater tumor kill”.

b. Quantity (how many cells you get back) – Envita’s AAIT immunotherapy comes with 100 times the cell dosage than the others.

c. Sterility (quality control measures) – Envita AAIT immunotherapy is completely contaminant free.

If you have any questions concerning Envita's AAIT immunotherapy, please consult with Envita's team of physicians and patient educators. This immunotherapy is offered at Envita’s international cancer center in Mexico.

Envita, for example, is proud to point out that it was approved to conduct a Phase I drug study regarding the body’s ability to utilize the immune system to fight cancer. Subsequently, Envita has researched, studied, and adopted numerous immunotherapy techniques over the last 10 years.